GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TTY Biopharm Co Ltd (ROCO:4105) » Definitions » Price-to-Owner-Earnings

TTY Biopharm Co (ROCO:4105) Price-to-Owner-Earnings : 13.30 (As of May. 12, 2025)


View and export this data going back to 2001. Start your Free Trial

What is TTY Biopharm Co Price-to-Owner-Earnings?

As of today (2025-05-12), TTY Biopharm Co's share price is NT$76.20. TTY Biopharm Co's Owner Earnings per Share (TTM) ended in Dec. 2024 was NT$5.73. It's Price-to-Owner-Earnings for today is 13.30.


The historical rank and industry rank for TTY Biopharm Co's Price-to-Owner-Earnings or its related term are showing as below:

ROCO:4105' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.06   Med: 20.4   Max: 54.43
Current: 13.47

During the past 13 years, the highest Price-to-Owner-Earnings of TTY Biopharm Co was 54.43. The lowest was 12.06. And the median was 20.40.


ROCO:4105's Price-to-Owner-Earnings is ranked better than
72.21% of 439 companies
in the Drug Manufacturers industry
Industry Median: 24.04 vs ROCO:4105: 13.47

As of today (2025-05-12), TTY Biopharm Co's share price is NT$76.20. TTY Biopharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$5.83. Therefore, TTY Biopharm Co's PE Ratio (TTM) for today is 13.07.

As of today (2025-05-12), TTY Biopharm Co's share price is NT$76.20. TTY Biopharm Co's EPS without NRI for the trailing twelve months (TTM) ended in was NT$5.79. Therefore, TTY Biopharm Co's PE Ratio without NRI for today is 13.16.

During the past 13 years, TTY Biopharm Co's highest PE Ratio without NRI was 29.71. The lowest was 11.25. And the median was 18.11.


TTY Biopharm Co Price-to-Owner-Earnings Historical Data

The historical data trend for TTY Biopharm Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TTY Biopharm Co Price-to-Owner-Earnings Chart

TTY Biopharm Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.65 14.54 18.15 22.85 12.70

TTY Biopharm Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.85 20.59 22.19 18.83 12.70

Competitive Comparison of TTY Biopharm Co's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TTY Biopharm Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where TTY Biopharm Co's Price-to-Owner-Earnings falls into.


;
;

TTY Biopharm Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

TTY Biopharm Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=76.20/5.73
=13.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TTY Biopharm Co  (ROCO:4105) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


TTY Biopharm Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of TTY Biopharm Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


TTY Biopharm Co Business Description

Traded in Other Exchanges
N/A
Address
No. 3-1, Park Street, 3rd Floor, Nangang District, Taipei, TWN, 11503
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in European and Other Countries. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.

TTY Biopharm Co Headlines

No Headlines